[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"morquio-a-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:morquio-a-syndrome":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100461082","non-invasive-functional-assessment-and-pathogenesis-of-morquio-a-100461082",false,"NCT05284006","Non-invasive Functional Assessment and Pathogenesis of Morquio A","Non-invasive Functional Assessment and Pathogenesis of Morquio A (NIFAMA)","NIFAMA","Inclusion Criteria:\n\n* Patients affected by MPS IVA. The diagnosis of MPS IVA is confirmed by deficient enzyme activity of \\\u003C 5% of normal activity level as measured in plasma or leukocytes.\n\nExclusion Criteria:\n\n* No","ALL",{"count":19,"type":20},60,"ESTIMATED","OBSERVATIONAL","Morquio A disease is a devastating systemic skeletal disease in which detailed progression and pathogenesis remain unknown. The proposed project aims to establish a non-invasive objective assessment that can be applicable to all ages of patients to better understand the progress of their disease and the most serious clinical problems (cervical instability and stenosis, tracheal obstruction, hyperlaxity of joints, hip dysplasia, and small lung capacity). The outcome of this project will lead to a more precise understanding of the skeletal\u002Fpulmonary compromise and defining clinical endpoints in this disease for future clinical trials of current or developing therapies.",[24,25,26],"Mucopolysaccharidosis IV Type A","Morquio A Syndrome","MPS IVA",[28,29,30,31,32],"skeletal dysplasia","GALNS","keratan sulfate","tracheal narrowing","short stature","RECRUITING","2026-05-11",{"date":36,"type":37},"2026-05-13","ACTUAL",{"date":39,"type":37},"2021-05-01",{"date":41,"type":20},"2027-04-30",{"name":43,"class":44},"Nemours Children's Clinic","OTHER"]